Loading page
Loading page
Loading substance route
Hold blotter sublingually for 15-30 minutes to ensure proper absorption. The compound exhibits minimal oral bioavailability and must not be swallowed immediately. Fatalities have been documented at heavy doses.
Effects vary widely by individual, dose, and context.
The physical effects of 25B-NBOMe can be broken down into six components all of which progressively intensify proportional to dosage.
The head space of 25B-NBOMe is described by many as remarkably light and underwhelming in comparison to the classical psychedelics. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout low to moderate dosages. At high dosages however, mild to overwhelming cognitive alterations become present.
The visual geometry that is present throughout this trip is often described as similar in appearance to that of LSD. They can be comprehensively described as algorithmic in geometric style, intricate in complexity, fine and zoomed out in detail, fast and smooth in motion, structured in shape, colourful in scheme, glossy in colour, sharp around the edges and mostly rounded across their corners. In comparison to other more commonly used psychedelics they can be described as significantly more intricate than the visual geometry found within 2C-I and most of the 2C-x family in general as well as completely on par with LSD, Psilocin and DMT at appropriately high dosages. In terms of their behaviour, 25B-NBOMe's geometry leads onto Level 7A visual geometry with Level 7B remaining so far unconfirmed within this substance. They also seem to consistently build up in visual intensity when the tripper stares at a central point. This eventually envelops the visual field and creates the sensation that the tripper has broken through into a continuously shifting geometric landscape or structure with a vast sense of immersive physical size attributed to it.
25B-NBOMe is capable of producing a full range of hallucinatory states within the level 1 - 3 range extremely consistently. However, level 4 hallucinatory breakthroughs are reported but very uncommon and inconsistent in comparison to other more commonly used psychedelics such as psilocin, 2C-E and DMT.
The auditory effects of 25B-NBOMe are common in their occurrence and exhibit a full range of effects.
25B-NBOMe has demonstrated reinforcing effects in rodent studies, producing conditioned place preference and self-administration with robust dopamine elevation in the nucleus accumbens. However, the rapid tolerance development that occurs immediately after ingestion makes compulsive use essentially impossible, and the substance is generally considered not habit-forming with desire to use often decreasing after experiences.
The lethal dosage has not been formally determined. 25B-NBOMe can be fatal at heavy doses, with at least one death attributed directly to the substance (a 17-year-old). Anecdotal reports suggest dangerous side effects begin appearing above 1000 μg, with doses around 2000 μg potentially lethal for more sensitive individuals. Individual response varies significantly, with some surviving much higher doses without major effects. The extreme potency in the microgram range and unpredictable dose-response relationship contribute to overdose risk, particularly with insufflation.
Vasoconstriction, tachycardia, and elevated blood pressure commonly occur during intoxication; in overdose situations these effects intensify significantly and may potentially result in organ failure or cardiac arrest.
Overdose effects commonly include confusion, delusions, panic attacks, and aggressive behavior. These psychotomimetic effects appear dose-dependent and are more likely at higher doses.
NBOMes have shown a tendency to cause severe seizures, which are commonly reported among overdose symptoms. The substance appears to lower seizure threshold.
25B-NBOMe was first described in the scientific literature by Ralf Heim and colleagues at the Free University of Berlin, with initial findings presented in conference abstracts as early as 1999. The compound was subsequently characterized in more detail through continued research at the institution…
Prohibited under the Suchtmittelgesetz (Narcotic Substances Act) since June 26, 2019. Possession, production, and sale are illegal.
Controlled under Schedule III of the Controlled Drugs and Substances Act as of October 31, 2016. Classified as a derivative of 2,5-dimethoxyphenethylamine.
Prohibited substance under Czech drug legislation.
Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since December 13, 2014. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without license are prohibited.
Designated as a narcotic drug under Japanese law, effective November 1, 2015.
Controlled as a Schedule 2 substance under the Misuse of Drugs Act.
Added to Schedule I (substances normally without medical use) as of August 1, 2013, published by the Medical Products Agency in regulation LVFS 2013:15.
Classified as a controlled drug. Possession, production, supply, and import are prohibited.
Placed in Schedule I of the Controlled Substances Act by the DEA in November 2013 using emergency scheduling powers, alongside 25I-NBOMe and 25C-NBOMe. Manufacturing, purchase, possession, processing, and distribution are prohibited.
Listed as a controlled substance under Portaria SVS/MS nº 344. Possession, production, and sale are prohibited.
Designated as a controlled substance as of October 2015 under national drug control regulations.
Listed in the government decree on substances, preparations, and plants considered to be narcotic drugs.
Classified as a Schedule 1 controlled substance under Italian drug legislation.
Classified as a Schedule I controlled substance under Latvian drug control legislation.
Prohibited as a narcotic drug since May 5, 2015 under Russian federal drug control legislation.
Specifically named as a controlled substance under Verzeichnis D of Swiss narcotics legislation.
Controlled as a Class A substance under the Misuse of Drugs Act 1971 through the N-benzylphenethylamine catch-all clause. Class A carries the most severe penalties for possession and supply.
